RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer

Reuters

2025/07/02

RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer

RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548355885"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548355885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548355885?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-02 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548355885","market":"fut","top_or_hot":-1,"title":"RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-02 00:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDHL","symbol_name":"Redhill Biopharma Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL82bqVY:1","article_id":"2548355885","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548355885","pubTimestamp":1751385635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer . This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. , is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDHL":"Redhill Biopharma Ltd","BK4007":"制药"},"translate_title":"RedHill Biopharma启动Opaganib/Darolutamide联合治疗晚期前列腺癌的2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDHL":0.9},"content_text":"RedHill Biopharma Launches Phase 2 Clinical Trial for Opaganib/Darolutamide Combination in Advanced Prostate Cancer\n    \n\n        RedHill Biopharma Ltd. has announced the initiation of patient recruitment for a Phase 2 clinical study to evaluate the efficacy of a combination treatment using opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). This study, sponsored by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), is supported by Bayer and the Ramsay Hospital Research Foundation. The study aims to recruit 60 participants across multiple sites in Australia and New Zealand and will use the PCPro™ lipid biomarker test to identify patients with a poor prognosis who are most likely to benefit from the treatment. Led by Professor Lisa Horvath, the study's primary endpoint is improved 12-month radiographic progression-free survival, with several secondary and exploratory endpoints also being evaluated. The results of the study will be presented in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO22154) on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}